secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001104659-23-030354
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar FY2022 net loss $28.6M ($4.05/share); cash $19.9M, runs to Q4 2023
----------------------------------------------------------------------------

- Net loss $28.6M ($4.05/share) vs $24.1M ($4.35/share) in 2021.
- Cash $19.9M at 12/31/22 vs $35.7M at 12/31/21; operating cash used $25.2M; funds into Q4 2023.
- R&D $19.2M (up $1.6M); G&A $9.5M (up $3.0M) from prior year.
- Lawsuit resolved with WARF; non-exclusive license secured; all claims against Drs. Weichert and Pinchuk dismissed.
- Appointed Shane Lea as CCO and Dr. Andrei Shustov as SVP Medical; positive clinical data including CNS lymphoma complete response.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465923030354/0001104659-23-030354-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465923030354/tm238997d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-030354

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer